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lipid protein (PLP), are easily detectable in specimens
of peripheral blood from normal individuals (Wucherp-
fennig et al., 1994; Steinman et al., 1995). Some exons
Multiple sclerosis (MS) is the most common autoimmune
of MBP encoded in the Golli±MBP gene (Pribyl et al.,disease involving the nervous system. In the United
1993) are actually expressed in the thymus during the
States z250,000 individuals suffer from MS. The first
development of the immune system and into adulthood.
clinical signs of MS typically begin in young adulthood,
T cell epitopes of MBP that are pathogenic in variousand women with the disease outnumber men 2:1. The
strains of mice are expressed in the thymus (Mathisencause of the disease is unknown, but genetic factors are
et al., 1993). Thus, there is an escape from negativeimportant. The concordance rate among monozygotic
selection for T cells reactive to certain myelin constit-twins is 30%, a 10-fold increase over dizygotic twins or
uents. The revelation that MBP is expressed in the thy-first-degree relatives (Ebers et al., 1986, 1995). The
mus has overturned the idea that this antigen, whichhigher incidence rate among monozygotic twins empha-
comprises z30% of the protein in the myelin sheath,sizes the importance of genetic factors, but the dis-
somehow represented a special example of an antigencordance rate of 70% among identical twins illuminates
that was altogether sequestered from the immune sys-the role of nongenetic factors on disease penetrance.
tem. It had generally been assumed that antigens suchThe fact that the prevalence of MS among nonbiological
as MBP were ªprotectedº from the immune system byfirst-degree relatives of MS index cases is similar to that
virtue of their predominant expression in the centralin the general population strongly supports a genetic
nervous system, which is separated in part from thebasis for familial clustering (Ebers et al., 1995). Among
immune system by the blood±brain barrier.genetic factors, HLA class II genes exert an influence,
Myelin-reactive T cells in the peripheral blood maywith HLA DR2 carrying a 4-fold relative risk for northern
become activated by microbes. The similarities betweenEuropean caucasoids (Altmann et al., 1991; Oksenberg
infectious pathogens and self-antigens may lead to in-et al., 1993a, 1993b). Geography plays an interesting
advertent autosensitization, in the course of an immunerole in determining susceptibility to MS. Among white
response to a microbe. This concept is called molecularpopulations, the prevalence of MS is highest in the tem-
mimicry. Molecular mimicry refers to structural homolo-perate regions of the world (Kurtzke, 1983). Migration
gies between a self-protein and a protein in a viral orfrom a location of high disease incidence to a location
bacterial pathogen. For example, MBP shares extensiveof low disease incidence after the age of 15 years carries
homologies at the amino acid level with a number ofwith it the risk associated with the location where one
common pathogens including measles, hepatitis B, in-dwelled during the first 15 years, while migration before
fluenza virus, and adenovirus (Wucherpfennig andthe age of 15 years carries the risk associated with the
Strominger, 1995). Residues 84±101 of MBP shareimmigrant's destination (Kurtzke, 1983).
stretches of four to six amino acids with influenza, Ep-A typical presentation of MS involves an initial course,
stein±Barr virus, herpes viruses, papilloma virus, andrunning for several years to more than a decade, mani-
various bacteria including pseudomonas (Wucherpfen-fest by episodes of relapse followed by remission. Re-
nig and Strominger, 1995). Various critical contact resi-lapses often follow an episode of a viral infection of
dues for binding to major histocompatibility complexthe upper respiratory system or gastrointestinal tract.
(MHC) molecules and the T cell receptor (TCR) are pres-In about one half of MS cases the disease progresses
ent in these microbial sequences. Microbes having ap-to a more chronic phase. The clinical symptoms of the
propriate amino acids at critical MHC and TCR contactdisease are entirely attributable to pathology in the cen-
sites can stimulate MBP-specific T cell clones from MStral nervous system. Clinical problems may include dis-
patients (Wucherpfennig and Strominger, 1995). It hasturbances in visual acuity, sometimes culminating in
been shown that one can induce EAE by immunizingblindness; double vision; motor disturbances affecting
with a peptide sequence from a pathogen with homologywalking and use of the hands; incoordination; bowel and
to MBP (Fujinami and Oldstone, 1985). Homology maybladder incontinence; spasticity; and sensory distur-
be necessary atonly a few of theamino acids comprisingbances including loss of touch, pain, and temperature
a T cell epitope. Conservation of the native amino acidand proprioception. Cognitive function is not impaired
sequence at only four of eleven amino acids of an MBPin MS. The pathology of the disease lies entirely in the
epitope is sufficient to induce EAE (Gautam et al., 1992).central nervous system and is characterized by a classic
Thus, tolerance to myelin components could be brokenpicture of inflammation surrounding venules and ex-
tending into the myelin sheath. Understanding the by an immune response to a microbe. This would be
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Figure 1. Stages in the Pathogenesis of Multiple Sclerosis
sufficient to trigger a relapse of MS or to initiate disease. (VCAMs), along with class II MHC molecules, are found
on inflamed endothelium (Brocke et al., 1994).Alternatively, superantigensÐwhich are microbial tox-
ins capable of stimulating whole populations of T cells Once the activated lymphocytes have extravasated,
they still must pass through a barrier of extracellularvia engagement of the TCR Vb chainÐare capable of
inducing relapses in animal models of MS (Brocke et matrix comprised of type IV collagen. Matrix metallopro-
teases play a key role in the penetration of this barrier,al., 1993) and are also capable of stimulating MBP-spe-
cific T cell clones. Thus, microbes may provide the stim- allowing the activated lymphocytes to gain access to the
white matter surrounding axons of the central nervousulus for induction of disease and may trigger relapses
by immunological cross-reactions with myelin. system. The matrix metalloproteases gelatinase A and
B with specificity for collagen type IV, found surroundingPenetration of the blood±brain barrier by activated
lymphocytes is a multistep process (Figure 1). There inflammed brain endothelium, allow activated lympho-
cytes to penetrate extracellular matrix. Both gelatinaseare specialized capillary endothelial cells in the central
nervous system that are nonfenestrated and connected A and B are detectable in the spinal fluid of MS patients,
and gelatinase B immunoreactivity is seen in MS lesionsthrough tight junctions. Activated lymphocytes are able
to diapedese (literally walk through) this barrier by virtue (Gijbels et al., 1992). Gelatinase B is present in MS le-
sions in endothelial cells, pericytes, macrophages, andof adhesion molecules such as integrins, particularly a4
integrin, and members of the immunoglobulin super- astrocytes.
The matrix metalloproteases are regulated in MS pa-gene family like CD4. Once activated, any T cell express-
ing very late antigen (VLA)±4 may bind to adhesion mole- tients. Gelatinase A and B are blocked by tissue inibitors
of matrix metalloproteases (TIMPs). TIMP-1 is presentcules on the surface of inflamed endothelium and begin
penetration of the capillary endothelium, the first part in the spinal fluid of MS patients and may act to inhibit
ongoing demyelination. Spontaneous resolution of mostof the blood±brain barrier (Brocke et al., 1994). Blockade
of VLA-4 reverses clinical paralysis in acute experimen- clinical relapses in MS is very common. TIMP-1 is induc-
ible by cytokines including TNFa, which is increasedtal autoimmune encephalomyelitis (EAE) and prevents
further relapses in the chronic model of this disease during acute relapses of MS.
When hydoxamic acid inhibitors of matrix metallopro-(Raine et al., 1990; Yednock et al., 1992). In acute MS
lesions, VLA-4 is found on T cells in the perivascular teases are given to animals paralyzed with EAE, disease
is reversed and further relapses can be inhibited (Gijbelslymphocytic cuff, and vascular cell adhesion molecules
Review: Multiple Sclerosis
301
et al., 1994). These compounds act by restoring the These efforts to determine which antigens trigger the
pathologic response in MS brain have very practicalintegrity of the blood±brain barrier. Upon cessation of
therapy, disease recurs within 24 hr. These hydroxamic consequences. It is now possible to induce immunologi-
cal tolerance to specific proteins using a variety of strat-acid inhibitors of matrix metalloproteases inhibit gela-
tinase B activity in the spinal fluid of MS patients. egies including altered peptide ligands, intravenous tol-
erance, oral tolerance, and blockade of costimulatoryOnce immune cells have spread to the white matter
of the central nervous system, the immune response is molecules. All of these approaches have been effective
in suppressing disease in animal models of MS. More-targeted to several different antigens on myelin: there
is a critical antibody response directed to myelin; the over, some of these approaches, like the use of altered
peptide ligandsÐwhich are peptides that are modifiedcomplement cascade is activatedwith membrane attack
complexes appearing in the spinal fluid; and T cells so that they engage the T cell receptor in a suboptimal
manner, and thereby alter Tcell signalingÐcan influenceare targeted to certain key portions of various myelin
antigens. The T cells in turn produce cytokines and then not only the response to a specific myelin antigen, but
can modulate the behavior of an entire inflammatoryinfluence macrophages to attack myelin and phagocy-
tose large chunks of the myelin sheath. This concerted ensemble. In MS and in EAE, there are diverse collec-
tions of T cells in the inflammatory infiltrate in whiteattack leads to areas of demyelination impairing salta-
tory conduction along the axon and producing the matter. Targeting a critical T cell in this diverse popula-
tion with a soluble peptide ligand for the T cell receptorpathophysiologic defect.
can lead to the rapid disappearance of the entire inflam-
matory infiltrate within 24 hr (Brocke et al., 1996). TheThe Specificity of the Immune Response to
the Myelin Supramolecular Complex mechanism underlying this observation involves down-
regulation of proinflammatory cytokines, like TNFa andWhat myelin components are targeted by T and B cells?
Immune responses to various components of the myelin interferon-g, and up-regulation of suppressive cyto-
kines. Apoptosis is also seen during resolution of thesheath have been detected in MS patients: immune re-
sponses to MBP, PLP, transaldolase, and 29,39 cyclic inflammatory response in the brain (Bauer et al., 1995).
The role of certain cytokines in MS is well established.nucleotide 39phosphodiesterases (CNP), as well as two
members of the immunoglobulin supergene family found T helper type 1 (Th1) cytokines such as interferon-g were
shown to worsen disease when given systemically toin the myelin sheath, myelin oligodendroglial glycopro-
tein (MOG) and myelin-associated glycoprotein (MAG), patients with MS (Panitch et al., 1987), and TNFa is
increased during exacerbations of MS (Sharief and Hen-are detected in MS patients (Steinman, 1995). Many of
these myelin components have been injected into labo- tges, 1991). The mechanisms by which Th1 cytokines
exacerbate MS may involve the ability of Th1 cytokinesratory animals that then develop EAE with inflammation
and demyelination in the central nervous system. In ad- to increase expression of MHC class II on endothelium
and up-regulate VLA-4. TNFa kills myelinating cells indition, some inducible heat shock proteins, including
crystallin-aB, can be detected in glial cells in MS lesions culture (Selmaj et al., 1991). Therapies aimed at down-
regulating TNFa with phosphodiesterase inhibitors orand can stimulate an immune response in MS patients.
The large number of antigens that can elicit an immune altered peptide ligands (Karin et al., 1994) appear prom-
ising for treatment of MS. Most recently, interferon-b,response in MS patients may represent the intermolecu-
lar dispersion of an immune response that arose initially which down-regulates interferon-g, has been shown to
reduce the relapse rate modestly in MS (Paty et al.,to a single component of myelin (Lehmann et al., 1992).
Multiple immune responses to several components of 1993).
As our understanding of the pathophysiology of MSa supramolecular structure, like the myelin sheath in
MS or the pyruvate dehydrogenase complex in primary increases, rational therapies will be devised that will
arrest the immunological attack onmyelin, withoutcaus-biliary cirrhosis, are common in individuals with autoim-
mune disease involving a discrete organ. ing widespread immune suppression. Once the immune
response is silenced, it will be important to repair theImmunity to some of these antigens is likely to play an
important role in the pathogenesis of MS. A key immune damaged myelin sheath. As possible methods to ac-
complish this repair, the use of oligodendroglial trans-response is targeted to certain regions of myelin basic
protein. The major T and B cell response in the central plants and growth factors to reinitiate myelination are all
nervous system of MS patients who are HLA DR2 (about currently under intense investigation (Steinman, 1993).
two thirds of patients) is directed to a region between
residues 84 and 103 of MBP (Steinman et al., 1995; Acknowledgments
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